203 related articles for article (PubMed ID: 35278299)
1. [Sotrovimab in controlling SARS-CoV-2 infection].
Płusa T
Pol Merkur Lekarski; 2022 Feb; 50(295):48-50. PubMed ID: 35278299
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate.
Touret F; Baronti C; Bouzidi HS; de Lamballerie X
Sci Rep; 2022 Mar; 12(1):4683. PubMed ID: 35304531
[TBL] [Abstract][Full Text] [Related]
4. Immune treatment in COVID-19.
Menéndez R; González P; Latorre A; Méndez R
Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):59-63. PubMed ID: 35488829
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
[TBL] [Abstract][Full Text] [Related]
6. A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab.
Passariello M; Ferrucci V; Sasso E; Manna L; Lembo RR; Pascarella S; Fusco G; Zambrano N; Zollo M; De Lorenzo C
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628365
[TBL] [Abstract][Full Text] [Related]
7. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.
Bruel T; Hadjadj J; Maes P; Planas D; Seve A; Staropoli I; Guivel-Benhassine F; Porrot F; Bolland WH; Nguyen Y; Casadevall M; Charre C; Péré H; Veyer D; Prot M; Baidaliuk A; Cuypers L; Planchais C; Mouquet H; Baele G; Mouthon L; Hocqueloux L; Simon-Loriere E; André E; Terrier B; Prazuck T; Schwartz O
Nat Med; 2022 Jun; 28(6):1297-1302. PubMed ID: 35322239
[TBL] [Abstract][Full Text] [Related]
8. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.
VanBlargan LA; Errico JM; Halfmann PJ; Zost SJ; Crowe JE; Purcell LA; Kawaoka Y; Corti D; Fremont DH; Diamond MS
Nat Med; 2022 Mar; 28(3):490-495. PubMed ID: 35046573
[TBL] [Abstract][Full Text] [Related]
9. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains.
Case JB; Mackin S; Errico JM; Chong Z; Madden EA; Whitener B; Guarino B; Schmid MA; Rosenthal K; Ren K; Dang HV; Snell G; Jung A; Droit L; Handley SA; Halfmann PJ; Kawaoka Y; Crowe JE; Fremont DH; Virgin HW; Loo YM; Esser MT; Purcell LA; Corti D; Diamond MS
Nat Commun; 2022 Jul; 13(1):3824. PubMed ID: 35780162
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series.
Cicchitto G; Cardillo L; Sequino D; Sabatini P; Adamo L; Marchitiello R; Viscardi M; Cozzolino L; Cavallera A; Bocchino M; Sanduzzi Zamparelli A; Ferrigno F; de Carlo E; de Martinis C; Fusco G
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680143
[TBL] [Abstract][Full Text] [Related]
11. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Rodrigues Falci D; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Parra S; Sager JE; Austin D; Peppercorn A; Alexander E; Yeh WW; Brinson C; Aldinger M; Shapiro AE;
JAMA; 2022 Apr; 327(13):1236-1246. PubMed ID: 35285853
[TBL] [Abstract][Full Text] [Related]
12. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Falci DR; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Hebner CM; Sager J; Mogalian E; Tipple C; Peppercorn A; Alexander E; Pang PS; Free A; Brinson C; Aldinger M; Shapiro AE;
N Engl J Med; 2021 Nov; 385(21):1941-1950. PubMed ID: 34706189
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
Yetmar ZA; Beam E; O'Horo JC; Seville MT; Brumble L; Ganesh R; Razonable RR
Transpl Infect Dis; 2022 Aug; 24(4):e13901. PubMed ID: 35848574
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Omicron variant emerged under immune selection.
Tan CW; Chia WN; Zhu F; Young BE; Chantasrisawad N; Hwa SH; Yeoh AY; Lim BL; Yap WC; Pada SKMS; Tan SY; Jantarabenjakul W; Toh LK; Chen S; Zhang J; Mah YY; Chen VC; Chen MI; Wacharapluesadee S; Sigal A; Putcharoen O; Lye DC; Wang LF
Nat Microbiol; 2022 Nov; 7(11):1756-1761. PubMed ID: 36195753
[TBL] [Abstract][Full Text] [Related]
15. Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
Ueno M; Iwata-Yoshikawa N; Matsunaga A; Okamura T; Saito S; Ashida S; Yoshida I; Nagashima M; Asakura H; Yaoita Y; Suzuki J; Sadamasu K; Yoshimura K; Kutsuna S; Shiwa-Sudo N; Nagata N; Suzuki T; Suzuki A; Okamoto M; Kimura M; Ohmagari N; Miura R; Ishizaka Y
Antiviral Res; 2022 May; 201():105297. PubMed ID: 35341809
[TBL] [Abstract][Full Text] [Related]
16. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies.
Arora P; Zhang L; Krüger N; Rocha C; Sidarovich A; Schulz S; Kempf A; Graichen L; Moldenhauer AS; Cossmann A; Dopfer-Jablonka A; Behrens GMN; Jäck HM; Pöhlmann S; Hoffmann M
Cell Host Microbe; 2022 Aug; 30(8):1103-1111.e6. PubMed ID: 35588741
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5.
Touret F; Baronti C; Pastorino B; Villarroel PMS; Ninove L; Nougairède A; de Lamballerie X
Sci Rep; 2022 Jul; 12(1):12609. PubMed ID: 35871089
[TBL] [Abstract][Full Text] [Related]
19. Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants.
Focosi D; Casadevall A; Franchini M; Maggi F
Viruses; 2024 Jan; 16(2):. PubMed ID: 38399991
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sotrovimab for vaccinated or unvaccinated patients with mild-to-moderate COVID-19 in the omicron era.
Izumo T; Awano N; Kuse N; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Ota H; Inomata M
Drug Discov Ther; 2022 Jul; 16(3):124-127. PubMed ID: 35753770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]